IGC Pharma, INC.
Our company has strategically built manufacturing and excellent technical expertise in Alzhemer's
IGC Pharma, INC.
IGC has adopted the following policies and charters to help ensure that it retains its integrity and merits public trust and confidence.
April 16, 2024
POTOMAC, Md., April 16, 2024
–(BUSINESS WIRE)–IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer’s at week two compared to placebo.
IGC-AD1 targets neuroinflammation and CB1 receptor dysfunction, and the investigational drug contains THC as one of two active pharmaceutical agents. THC is a principal psychoactive cannabinoid found in Cannabis. IGC-AD1 is a first-of-its-kind THC-based-formulation undergoing a formal Phase 2 clinical trial in Alzheimer’s disease (clinicaltrials.gov, Identifier: CT05543681).
